Biotechnology Industry Organization
Charles Ludlam to VP-government affairs succeeding Lisa Raines, who left the association to join Genzyme as a VP. Ludlam was previously the Senate Small Business Committee's chief tax counsel and a long- time aide to committee Chairman Bumpers (D-Ark.). Bumpers is a sponsor of legislation that would reduce capital gains taxes on start-up companies, a bill endorsed by the biotechnology industry. The merger of the Industrial Biotechnology Association and Association of Biotechnology Companies to form BIO becomes official July 1.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth